February 2022
214 articles-
Feb 28 · 00:24Biotechnology Daily
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure
-
Feb 28 · 00:22Biotechnology Daily
Veracyte's prostate cancer genomic test can guide patients to best treatment, study finds
-
Feb 28 · 00:21Biotechnology Daily
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says
-
Feb 28 · 00:19Biotechnology Daily
Digital stethoscope maker Tyto Care nabs European approval for its lung sound-identifying AI
-
Feb 28 · 00:17Bio Business News
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline
-
Feb 28 · 00:13Bio Business News
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy
-
Feb 28 · 00:00Bio Business News
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech
-
Feb 27 · 23:58Bio Business News
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO
-
Feb 27 · 23:48Market Watch
Asian markets mixed amid Ukraine war, Russia sanctions, energy worries
-
Feb 27 · 23:45Market Watch
New Hope Coal Sales, Earnings Rise
-
Feb 24 · 23:43Biotechnology Daily
Larimar kept in limbo as FDA maintains clinical hold on leading candidate
-
Feb 24 · 23:41Biotechnology Daily
Legend's early-stage CAR-T on FDA hold after single patient dosed
-
Feb 24 · 23:37Biotechnology Daily
AC Immune's Janssen-partnered Alzheimer's vaccine spurs tau-attacking antibodies in early-stage trial
-
Feb 24 · 23:33Biotechnology Daily
Deleting a gene in mice helps delay age-related inflammation
-
Feb 24 · 23:31Bio Business News
Quantum-Si taps founder Rothberg, prolific medtech entrepreneur, as interim CEO
-
Feb 24 · 23:29Bio Business News
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies
-
Feb 24 · 23:27Bio Business News
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end
-
Feb 24 · 23:25Bio Business News
Kallyope, with ex-Merck exec at helm, skirts 'less desirable' public markets with $236M series D
-
Feb 24 · 22:58Market Watch
Tapestry Inc. stock remains steady Thursday, underperforms market
-
Feb 23 · 23:16Biotechnology Daily
How a family of enzymes meant to stave off viruses can lead to 'cyclones' that drive cancer
-
Feb 23 · 23:13Biotechnology Daily
To incentivize organ donations, DaVita offers employees extra PTO
-
Feb 23 · 23:10Biotechnology Daily
Musk's Neuralink disputes accusations of animal abuse in brain implant experiments
-
Feb 23 · 23:05Biotechnology Daily
Improving RNA editing for genetic diseases by recruiting the body's natural protein
-
Feb 23 · 23:03Bio Business News
With $1.7T in the coffers, biopharma M&A expected to be 'a different animal' in 2022